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Preoperative cisplatin/fluorouracil is used for the treatment of localised oesophageal carcinoma. This phase II study aimed to assess
the efficacy and safety of administering preoperative epirubicin/cisplatin/capecitabine (ECX). Patients with stage II or III oesophageal/
gastro-oesophageal junctional adenocarcinoma from one institution received 4 cycles of ECX (epirubicin 50mgm
 2 day 1, cisplatin
60mgm
 2 day 1, capecitabine 625mgm
 2 b.i.d. daily) followed by surgery. The primary end point was the pathological complete
response (pCR) rate based on a Simon two-stage design. Secondary end points included overall and progression-free survival (OS/
PFS). Thirty-four patients were recruited: median age 60 years (range 41–81), 91% male, 97% PS 0/1, 80% T3, 68% N1. Thirty-one
patients completed four ECX cycles. Grade 3/4 toxicities X5% included neutropenia (62%), hand–foot syndrome (15%) and nausea/
vomiting (9%). Thirteen out of 28 (46%) evaluable patients responded to chemotherapy by EUS (X30% reduction in maximal
tumour thickness). Twenty-six out of 34 (76%) patients underwent resection (R0¼73%, R1¼27%). Post-operatively, two patients
died within 60 days of surgery. The pCR rate was 5.9% (95% CI 0–14%) in the intent-to-treat population. According to the statistical
design, this prompted early study termination. However, with a median follow-up of 34 months the median OS and 1- and 2-year
survival rates were 17 months, 67 and 39% respectively. Median PFS was 13 months. Of the 14 relapsed patients, 10 presented with
distant metastases. Preoperative ECX is feasible and well tolerated. Although associated with a low pCR rate, survival with ECX was
comparable with published studies suggesting that pCR may not correlate with satisfactory outcome from preoperative
chemotherapy for localised oesophageal adenocarcinoma.
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Although the prevalence of distal gastric cancer has declined, the
world-wide incidence of distal oesophageal and gastro-oesophageal
junctional (GOJ) adenocarcinoma is increasing (Blot et al, 1991;
McCann, 1999; Pera et al, 2005). It is estimated that over 462000
new cases of oesophageal cancer were diagnosed world-wide in
2002 accounting for 386000 deaths (Parkin et al, 2005). For
patients who present with localised oesophageal adenocarcinoma
surgery remains the cornerstone of treatment, potentially improv-
ing long-term survival. However, despite radical resection, 5-year
survival rates range from only 15–39% (Malthaner et al, 2006).
Several surgical adjuncts have been investigated to improve
prognosis. Preoperative chemotherapy offers the potential for
tumour downstaging, early symptom improvement, enhanced
resectability, the demonstration of in vivo chemosensitivity, the
early treatment of micrometastatic disease and improvement in
disease-free and overall survival (OS). This approach is supported
by the results of the Medical Research Council (MRC) randomised
trial of 802 patients with localised oesophageal cancer, which
showed a significant improvement in 2-year survival for pre-
operative cisplatin/fluorouracil compared with the surgery alone
(43 vs 34%, respectively) with both the adenocarcinoma and
squamous carcinoma subgroups appearing to benefit (MRC, 2002).
With a longer median follow-up of 6 years, the 5-year survival for
the preoperative chemotherapy vs surgery alone arms was still
significantly better (23 vs 17%) (Allum et al, 2008). In contrast, the
US Intergroup 113 trial of 440 patients failed to show an advantage
for peri-operative cisplatin/fluorouracil vs surgery alone in
oesophageal cancer (2-year survivals of 35 vs 37%, respectively)
leading to variation in the uptake of this practice (Kelsen et al,
1998). However, in a separately published subgroup analysis,
responders to preoperative chemotherapy (as gauged by barium
oesophagrams) had a significantly better outcome than non-
responders (Kelsen et al, 2007). In a systematic review of 11
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srandomised studies involving 2019 patients with oesophageal
carcinoma, preoperative cisplatin-based chemotherapy appeared
to confer a survival advantage with a hazard ratio (HR) of
0.88 (95% confidence interval (CI) 0.75–1.04) (Malthaner et al,
2006).
The preoperative chemotherapy approach to localised oesopha-
geal cancer may be optimised by the incorporation of more
effective cytotoxic agents. The epirubicin/cisplatin/fluorouracil
(ECF) triplet regimen is effective in the treatment of advanced
gastro-oesophageal cancer (Webb et al, 1997; Ross et al, 2002) and
when given as part of a peri-operative strategy for the treatment of
localised gastric and lower oesophageal/GOJ adenocarcinoma,
resulting in a significant improvement in 5-year survival compared
with surgery alone (36 vs 23%) (Cunningham et al, 2006). Recently,
capecitabine (X) and oxaliplatin (O) were found to be as effective
as fluorouracil and cisplatin, respectively, when substituted in the
ECF regimen for treating advanced gastro-oesophageal cancer
(Cunningham et al, 2008). The epirubicin/cisplatin/capecitabine
(ECX) and EOX regimens provide more convenient treatment
alternatives to ECF (no requirement for an indwelling central
venous access device or hydration for oxaliplatin) with certain
toxicity advantages.
In patients with oesophageal adenocarcinoma long-term survi-
val is strongly correlated with the achievement of pathological
complete response (pCR) to neoadjuvant chemoradiotherapy
(Walsh et al, 1996; Geh et al, 2001; Urba et al, 2001; Berger et al,
2005; Burmeister et al, 2005; Rohatgi et al, 2005). However, in the
US Intergroup and OEO2 trials of preoperative chemotherapy, the
pCR rates were only 2 and 4%, respectively (Kelsen et al, 1998;
MRC, 2002). With the emergence of more effective combination
chemotherapy regimens there is potential to improve preoperative
chemotherapy-associated pCR rates and thus survival. As a
potential surrogate for outcome, pCR could facilitate the reporting
of results from phase II trials, OS being the preferred outcome
measure for phase III trials.
The aim of this single centre phase II study was to assess the
pCR rate associated with preoperative ECX in patients with
localised, operable oesophageal and GOJ adenocarcinoma and to
evaluate OS, progression-free survival (PFS), toxicity and patterns
of treatment failure.
METHODS
Patients
Eligible patients were older than 18 years, had histologically
proven adenocarcinoma of the thoracic oesophagus or GOJ
(Siewert’s types I–III), American Joint Committee on Cancer
(AJCC) stage II or III (T2-3, N0-1, M0) disease, an Eastern
Cooperative Group (ECOG) performance status p2 and adequate
renal, hepatic and bone marrow function. Exclusion criteria
included locally advanced (T4) or metastatic disease (including
M1a), prior chemotherapy or radiotherapy, any clinically sig-
nificant uncontrolled co-existing illness or previous malignant
disease and complete dysphagia. This single institution trial was
approved by the local Ethics and Scientific Review Committees and
all patients provided written informed consent.
Pre-treatment evaluation
Patients underwent staging computed tomography (CT) of the
chest/abdomen/pelvis and endoscopic ultrasound (EUS) within 28
days of the first treatment. Laparoscopy and positron emission
tomography (PET) were performed where indicated. Glomerular
filtration rate was determined by 24h urinary clearance or EDTA
testing. Audiography and echocardiography or multiple-gated
acquisition scanning were performed when clinically indicated.
Operability was determined by a multi-disciplinary team following
this evaluation.
Treatment
Preoperative chemotherapy Chemotherapy was administered for
four cycles preoperatively. Each cycle comprised epirubicin
(50mgm
 2) on day 1 by intravenous bolus, cisplatin (60mgm
 2)
intravenously on day 1 with pre- and post-hydration and oral
capecitabine (625mgm
 2 twice daily) continuously throughout
treatment. Before each cycle of chemotherapy, a full blood count
and biochemical function (including renal and liver parameters)
were checked. Adverse events were assessed at every treatment
visit and were graded according to the National Cancer Institute
Common Toxicity Criteria (NCI-CTC) version 2.0. Dose modifica-
tions were instituted as previously described (Sumpter et al, 2005).
Cisplatin was discontinued in the presence of clinically significant
ototoxicity or peripheral neuropathy and substituted by carbopla-
tin at the discretion of the investigator. Epirubicin was omitted if
there was a clinically significant deterioration in cardiac function
confirmed by echocardiography (although cumulative dose only
200mgm
 2).
Surgery Post-chemotherapy evaluation included repeat CT chest/
abdomen/pelvis and EUS reviewed by the multi-disciplinary team.
Patients with stable or responding disease who remained fit for
surgery proceeded to surgery 4–6 weeks after the last cycle of
chemotherapy. Surgery was undertaken within one regional high-
volume centre (the majority by one surgeon) and was determined
by the location and extent of the localised tumour. Patients with
Siewert type I or II junctional cancers were treated by right
thoraco-abdominal oesophago-gastrectomy with two field lymph
node dissection. Those with type III tumours underwent extended
total gastrectomy with D2 lymphadenectomy using either a
transhiatal approach or a left thoraco-abdominal approach.
Resection of other organs was only included if there was evidence
of local infiltration. Post-operative complications, and any deaths
following surgery were recorded.
Patients deemed inoperable due to progression with loco-
regional disease were considered for definitive chemoradiation
where appropriate. Patients deemed inoperable at surgery due to
metastatic disease were followed up and treated according to the
local protocols.
Post-treatment evaluation and follow-up
Resected tumours were reviewed for histopathological response by
one histopathologist according to TMN staging after neoadjuvant
chemotherapy. The specimens were inflated and pinned to reduce
shrinkage of the oesophagus, sliced perpendicular to the lumen in
their entirety to give 5mm slices and each slice was embedded and
processed for histological examination. The whole length of the
tumour was examined to exclude the possibility of missing small
foci of residual tumour. Tumours were examined for pCR defined
as the inability of the pathologist to identify viable malignant cells
within the resected specimen. All patients had a post-surgery
baseline CT scan and were followed up at 3 monthly intervals for
the first year, 6 monthly intervals for the second year and annually
thereafter. CT scans (chest/abdomen/pelvis) were routinely
performed at 1 and 2 years after surgery and otherwise when
clinically indicated.
Statistical analysis
The primary end point was the pCR rate in the intent-to-treat
population. A Simon’s two-stage design (Chen and Shan, 2008) was
used based on a lower limit of a pCR rate of 5% (p0) and an
acceptable pCR rate of 15% (p1). With a calculated sample size of
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s33 patients, the study would stop early if a response rate of lower
than 5% was observed with 80.1% power (a¼0.049). Thus, if p2
pCRs were observed, the study would terminate due to lack of
efficacy, conversely if X6 pCRs were observed, then a conclusion
of efficacy would be reached and the trial stopped. If neither
criteria was met, the study would proceed to the second stage,
recruiting an additional 20 patients (total n¼53), concluding
efficacy only if X6 pCRs were observed. Seven additional patients
could be recruited to address the potential dropouts.
Secondary end points included OS and PFS, objective response
rate by CT and EUS (EUS response was considered to be 430%
reduction in maximal tumour thickness), toxicity and patterns of
treatment failure. Overall survival was calculated from the date of
study registration to the date of death from any cause. Progres-
sion-free survival was calculated from the date of study registra-
tion to the date of first documented progression or death. Patients
remaining alive or lost to follow-up were censored at the date of
last follow-up. Survival was calculated according to the Kaplan–
Meier method.
RESULTS
Patients
Between November 2002 and June 2007 34 patients were recruited,
all eligible for the study. The median age was 60 years (range 41–
81 years), most patients were of performance status 0/1 and the
majority had T3 disease (79.4%) with nodal involvement as
assessed by EUS. Patient characteristics are indicated in Table 1.
Treatment
Chemotherapy The median number of preoperative cycles of
chemotherapy delivered was 4. Thirty-one patients completed all
four cycles. Two patients received only 1 and 3 cycles, respectively,
due to progressive disease on therapy as assessed by CT, and one
patient received three cycles due to toxicity. For the cohort of 34
patients, the mean cumulative doses of epirubicin, cisplatin and
capecitabine were 181, 221 and 93gm
 2, respectively (i.e., 90, 92
and 89% of the planned cumulative doses, respectively). By EUS,
13 of the 28 assessable patients had a response and 15 patients had
stable disease.
Surgery Twenty-six patients were resected (76% of the 34
patients) after preoperative chemotherapy. One additional resected
patient did not have protocol-specified preoperative therapy and
was excluded from the resection analysis (considered inoperable
after four cycles of chemotherapy, but resected after a subsequent
course of chemoradiation). Reasons for not proceeding to
resection included progressive disease during preoperative chemo-
therapy (n¼2), inoperable at laparotomy due to peritoneal/liver
metastases undetected by preoperative imaging (n¼4) and
tumour considered too bulky on preoperative imaging (n¼1).
Of the 26 resected patients, 21 patients underwent oesophago-
gastrectomy and 6 patients underwent extended total gastrectomy.
Nineteen patients achieved R0 resections (no evidence of residual
macroscopic or microscopic disease at margins) (73%; 95% CI
56 90 or 56% on an intent-to-treat basis) and seven had R1
resections by virtue of microscopic disease within 1mm of the
circumferential resection margins. Of the seven patients who had
R1 resections, four received radical post-operative chemo-
radiotherapy.
Pathological findings
In the group of 26 resected patients, pCR was seen in 2 patients
which represents a pCR rate of 7.4% (95% CI 0–17) or 5.9% (95%
CI 0–14) in the intent-to-treat population, which met the criteria
for early study termination due to lack of treatment efficacy based
on pCR. Twelve patients experienced pathological T downstaging
compared with the initial EUS T stage and five of these were EUS
responders.
Survival
With a median follow-up of 34 months, 12 patients remain alive
(9 disease-free). For the 34 patients in the intent-to-treat
population, the median OS is 17 months (95% CI 12–22) and 1
and 2-year survivals are 67% (95% CI 48–80%) and 39% (95% CI
23–55%), respectively (Figure 1A). The median PFS is 13 months
(95% CI 11–16), Figure 1B. Overall survival according to R
resection status for the 26 resected patients is shown in Figure 2
and indicates a nonsignificant trend for improved survival in the
R0 vs R1 group (HR 2.1; 95% CI 0.7–7.0; P¼0.2). Both
patients who achieved pCR developed systemic recurrent disease
within 1 year (one with brain metastases and the other with
peritoneal disease). In an exploratory analysis, OS according to
EUS response was performed (Figure 3) and indicates a
nonsignificant trend for improved survival for EUS responders
compared with non-responders (HR 2.0; 95% CI 0.9–5.1; P¼0.2).
Eleven patients proceeded to receive systemic chemotherapy for
advanced disease.
Chemotherapy-related toxicity and surgical complications
Adverse events that occurred during chemotherapy are documen-
ted in Table 2. There were no chemotherapy-related deaths during
preoperative chemotherapy. One patient who received only one
cycle of chemotherapy died within 30 days of chemotherapy of
objectively documented progressive disease. One patient died after
54 days of surgery with a chronic history of chest problems
complicated by surgery and one other died after 31 days due
Table 1 Patient characteristics
N¼34
Median age, years (range) 60 (41–81)
Sex
Male 31 (91%)
Female 3 (9%)
ECOG performance status
0 9 (26%)
1 24 (71%)
2 1 (3%)
Histology
Adenocarcinoma 34 (100%)
Siewert’s classification
Type I 18 (53%)
Type II 12 (35%)
Type III 4 (12%)
T stage
T2 7 (21%)
T3 27 (79%)
N Stage
N0 11 (32%)
N1 23 (68%)
N2 0 (0%)
M stage
M0 34 (100%)
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sto post-operative chylous leak complicated by renal failure
(malignant cells were identified in the chylous fluid). Post-
operative complications occurring in greater than 5% of patients
included respiratory complications (n¼5), chylous leak (n¼2),
recurrent laryngeal nerve palsy (n¼2) and renal failure (n¼2).
For the 26 patients undergoing resection, first sites of recurrence
are indicated in Table 3.
DISCUSSION
In this phase II study of 34 patients with operable gastro-
oesophageal adenocarcinoma, preoperative ECX was associated
with a pCR rate of only 5.9% in the intent-to-treat population. This
resulted in early termination of the study based on the statistical
premise of the trial, which used pCR as the primary end point. This
3 6 9 17 R0 (N=19)
1 1 3 4 R1 (N=7)
Number at risk
0
20
40
60
80
100
Years
%
 
S
u
r
v
i
v
a
l
P=0.2
R0 (N=19)
R1 (N=7)
1 02 3 4
Figure 2 Overall survival according to R resection status (N¼26).
2 4 6 10 13 CR/PR (N=13)
1 1 4 9 15 s.d. (N=15)
Number at risk
0
20
40
60
80
100
Years
%
 
S
u
r
v
i
v
a
l
P=0.2
s.d. (N=15)
CR/PR (N=13)
1 02 3 4
Figure 3 Overall survival according to EUS response (N¼28) – on the
basis of evaluable patients for whom measurement of maximal tumour
thickness was available pre- and post-chemotherapy. Reasons for patients
being non-evaluable included death from progressive disease (n¼1),
stenotic lesion (n¼1), EUS data unavailable (n¼2), thickness not recorded
on second EUS (n¼2).
4 7 12 22 34
0
20
40
60
80
100
Years
%
 
S
u
r
v
i
v
a
l
3 5 7 17 34 Number at risk
0
20
40
60
80
100
Years
%
 
P
r
o
g
r
e
s
s
i
o
n
-
f
r
e
e
 
s
u
r
v
i
v
a
l
Number at risk
1 02 3 4
1 02 3 4
A
B
Figure 1 Overall and progression-free survival in the intent-to-treat
population. (A) Overall survival. (B) progression-free survival.
Table 2 Adverse events during preoperative chemotherapy (N¼34)
All grades, n (%) Grade 3/4, n (%)
Haematological
Neutropenia 32 (94) 21 (62)
Anaemia 26 (76) 3 (9)
Thrombocytopenia 8 (24) 0 (0)
Febrile neutropenia 1 (3) 1 (3)
Gastrointestinal
Nausea and vomiting 26 (76) 3 (9)
Diarrhoea 15 (44) 1 (3)
Stomatitis 13 (38) 0 (0)
Skin
Hand–foot syndrome 22 (64) 5 (15)
Neurological
Peripheral neuropathy 8 (24) 1 (3)
Constitutional
Fatigue 34 (100) 1 (3)
Table 3 First sites of recurrence for patients undergoing resection
(N¼26) (documented relapse, N¼14)
Number of patients
Site of recurrence R0, N¼19 R1, N¼7
Local – (resection bed/anastomosis/
local lymph nodes)
13
Distant
a 53
Local and distant 2 0
No recurrence 9 0
Death without documented recurrence 2 1
aFour patients showed recurrence at more than one site. Sites of distant recurrence
included distant nodes (N¼6), peritoneum (N¼3), lung (N¼2), brain (N¼1), liver
(N¼1) and bone (N¼1).
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lead to improved pCR rates compared with those observed in trials
of preoperative cisplatin/5FU (Kelsen et al, 1998; MRC, 2002) and
highlights the potential limitations of pCR as a primary end point
and surrogate marker of outcome for preoperative chemotherapy.
Paradoxically, both patients who achieved pCRs in this study
relapsed within 1 year of surgery. The early treatment and
potential elimination of micro-metastatic disease may actually be
the critical factor in conferring a survival advantage to systemic
neo-adjuvant therapy for localised oesophageal cancer. Alternative
regimens, for instance those incorporating docetaxel, may result in
higher pCR rates in phase II evaluation (Lorenzen et al, 2007) but
whether this translates into improved survival has yet to be shown.
The median and 2 year survivals of 17 months and 39%,
respectively, are comparable to those observed in the MRC and
Intergroup trials of preoperative cispatin/fluorouracil (Kelsen et al,
1998; MRC, 2002). However, our study was not powered around
survival, included patients mainly with T3 N1 disease and excluded
squamous carcinoma, which may account for the reason for
survival that did not appear to be greater with an effective triplet
regimen. Another consideration is the accuracy of histological
assessment of pCR, particularly when used as a primary end point.
However, standard histopathological review protocols are likely to
be accurate in this regard (Chang et al, 2007), and in our
institution all histopathological examination was performed by a
single experienced gastrointestinal pathologist. There are no other
validated scores of tumour regression in response to preoperative
therapy in oesophageal cancer, although recently one group
defined responders and non-responders as those with p or
410% residual tumour cells, respectively, in the resected specimen
(Weber et al, 2001; Brucher et al, 2006; Ott et al, 2006), and thus
pCR remains the standard assessment of histopathological
response.
The PCR rates associated with preoperative chemoradiation, the
other major treatment strategy for localised oesophageal carcino-
ma commonly used in North America, range from 15 to 33% for
the randomised controlled trials, which included patients with
adenocarcinoma (Walsh et al, 1996; Urba et al, 2001; Burmeister
et al, 2005; Tepper et al, 2008). Although higher than those
achieved with preoperative chemotherapy, these pCR rates have
failed to translate into a consistent survival advantage for
preoperative chemoradiation, the two positive studies being
criticised for unusually poor survival in the surgery alone arm
(Walsh et al, 1996) and for early termination due to poor
recruitment (Tepper et al, 2008). A recent meta-analysis of trials of
preoperative therapy in localised oesophageal carcinoma showed a
similar survival advantage for the subgroup of patients with
adenocarcinoma treated with chemoradiation (n¼345, HR 0.75,
95% CI 0.59–0.95; P¼0.02) and chemotherapy alone (n¼533, HR
0.78, 95% CI 0.64–0.95; P¼0.014) (Gebski et al, 2007).
Notably, there appeared to be a survival advantage in the pooled
analysis for squamous carcinoma treated with preoperative
chemoradiation but not preoperative chemotherapy, in contrast
to observations from subgroup analysis by histology of the MRC
trial (Allum et al, 2008). Differential treatment effects have earlier
been noted according to histology underscoring that squamous
carcinoma and adenocarcinoma are separate clinical and biological
entities.
The toxicity associated with preoperative ECX was reasonably
consistent with that reported for the regimen in the treatment of
advanced disease (Cunningham et al, 2008). The R0 resection rate
of 73% is higher than that reported in the MRC and Intergroup
trials (60 and 63%, respectively) (MRC, 2002; Kelsen et al, 1998)
and the frequency of post-operative complications was low.
Subgroup analysis in both the MRC and Intergroup trials indicated
that R0 resection was associated with significantly better survival
as compared with R1 resection or less with a 3-year OS of 42 vs
18% (Allum et al, 2008) and 39 vs 12% (Kelsen et al, 2007)
for R0 vs R1 resection, respectively. In this study, there was a
trend towards improved survival for patients achieving an R0
compared with an R1 resection, which did not reach statistical
significance and is likely to reflect the small patient numbers.
The majority of patients relapsing after resection presented with
distant metastases, consistent with earlier observations in oeso-
phageal and GOJ adenocarcinoma (Wayman et al, 2002), and
highlighting the need for surgical adjuncts incorporating effective
systemically directed therapies in this disease. Preoperative
approaches remain the most extensively investigated with only a
limited number of small negative randomised trials assessing
adjuvant therapy mainly in squamous carcinoma (Malthaner et al,
2004).
Accurate assessment of response to preoperative therapy and its
correlation with outcomes may facilitate the rationalisation of
further treatment, limit surgery-related morbidity and mortality
and optimise outcomes. As compared with CT and oesophago-
gastroscopy, EUS is more reliable for determining response to
preoperative therapy (Brown et al, 2004; Westerterp et al, 2005). In
an exploratory analysis, we attempted to assess the potential of
EUS as a tool for outcome prediction to preoperative chemother-
apy, evaluating the change in maximal tumour thickness with a
decrease of X30% representing a response, the cut-off value
utilised in RECIST and a simple response classifier. Response
according to EUS and its correlation with outcomes, such as
pathological response and survival, has previously been shown in
small studies of neoadjuvant therapy for oesophageal cancer
(Hirata et al, 1997; Chak et al, 2000; Willis et al, 2002; Masaho et al,
2005). In our analysis, there was no difference in OS between EUS
responders and non-responders to preoperative chemotherapy and
is likely to reflect the small number of patients. In addition, EUS is
limited in its inability to distinguish post-treatment fibrosis and
inflammation from tumour (Lightdale and Kulkarni, 2005).
A more promising imaging biomarker for outcome prediction to
preoperative chemotherapy further along in evaluation is meta-
bolic response by PET. Having been identified retrospectively
(Weber et al, 2001) and validated prospectively (Ott et al, 2006),
the feasibility of an early metabolic response-adjusted treatment
algorithm has been confirmed in a non-randomised trial (Lordick
et al, 2007), and randomised assessment of this biomarker-driven
treatment strategy is planned. There is also currently extensive
investigation to identify predictive and prognostic molecular
markers and signatures.
Efforts to improve the preoperative chemotherapy approach to
localised oesophageal cancer include the incorporation of
newer more effective cytotoxics including the taxanes, oxaliplatin
and capecitabine and targeted agents such as bevacizumab. In an
ongoing UK phase III trial of the MRC patients with oesophageal/
GOJ (types I and II) adenocarcinoma are randomised between
two cycles of cisplatin/fluorouracil and four cycles of ECX with OS
as the primary end point. This study was designed as a
prelude to the MRC trial, partly to provide some initial safety
data on preoperative ECX, as the randomised study of ECF vs the
capecitabine and oxaliplatin regimens in the advanced
disease setting (Cunningham et al, 2008) had not reported at that
time. Many patients at our institution preferentially enrolled
in the randomised trial following its launch in 2004. In
another ongoing trial of the MRC, patients with gastric and type
III GOJ adenocarcinoma are randomised between six cycles of pre-
and post-operative ECX or the same with the addition of
bevacizumab. The present phase II trial indicated the
safety and feasibility of administering preoperative ECX for
oesophageal and GOJ tumours, that preoperative
chemotherapy is associated with low pCR rates and the limitations
of pCR as a surrogate marker of outcome for preoperative
chemotherapy.
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